| abstract |
The present invention relates to the development of a pharmaceutical composition characterized by comprising triancinolone, bupivacaine and ethanol in the form of a suspension, the use thereof characterized by being for the preparation of a drug for treating neuropathic pain, chronic degenerative disease-related pain and post-operative pain in small and large animals. The neurolytic suspension proposed promotes potent long-lasting neurolysis by means of perineural infiltration, without local adverse reactions, resulting in the therapeutic effect of eliminating pain, said neurolytic suspension being recommended for neuropathic pain, chronic degenerative conditions and post-operative pain in large and small animals. |